Wikipedia:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Volociximab: Difference between pages
(Difference between pages)
Content deleted Content added
Saving copy of the {{drugbox}} taken from revid 460520254 of page Volociximab for the Chem/Drugbox validation project (updated: 'CAS_number'). |
Entranced98 (talk | contribs) Adding local short description: "Monoclonal antibody", overriding Wikidata description "chemical compound" |
||
| Line 1: | Line 1: | ||
| ⚫ | |||
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid [{{fullurl:Volociximab|oldid=460520254}} 460520254] of page [[Volociximab]] with values updated to verified values.}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
| Watchedfields = changed |
|||
| verifiedrevid = |
| verifiedrevid = 470631639 |
||
| image = |
| image = |
||
<!-- Monoclonal antibody data --> |
|||
| ⚫ | |||
| type = mab |
| type = mab |
||
| mab_type = mab |
| mab_type = mab |
||
| source = xi/o |
| source = xi/o |
||
| target = α5β1 [[integrin]] |
| target = [[Alpha-5 beta-1|α5β1]] [[integrin]] |
||
| ⚫ | |||
| ⚫ | |||
| tradename = |
| tradename = |
||
| pregnancy_AU = |
| pregnancy_AU = |
||
| Line 22: | Line 21: | ||
| legal_status = |
| legal_status = |
||
| routes_of_administration = |
| routes_of_administration = |
||
| ⚫ | |||
| ⚫ | |||
| bioavailability = |
| bioavailability = |
||
| protein_bound = |
| protein_bound = |
||
| Line 29: | Line 27: | ||
| elimination_half-life = |
| elimination_half-life = |
||
| excretion = |
| excretion = |
||
| ⚫ | |||
| ⚫ | |||
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
||
| ChemSpiderID = |
| ChemSpiderID = none |
||
| CAS_number_Ref = {{cascite| |
| CAS_number_Ref = {{cascite|changed|??}} |
||
| CAS_number = |
| CAS_number = 558480-40-3 |
||
| ATC_prefix = none |
| ATC_prefix = none |
||
| ATC_suffix = |
| ATC_suffix = |
||
| Line 44: | Line 41: | ||
| KEGG_Ref = {{keggcite|correct|kegg}} |
| KEGG_Ref = {{keggcite|correct|kegg}} |
||
| KEGG = D06319 |
| KEGG = D06319 |
||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| molecular_weight = 145.5 [[kDa]] |
|||
}} |
}} |
||
'''Volociximab''' (also known as M200) is a [[Chimeric protein|chimeric]] [[monoclonal antibody]] jointly developed by [[PDL BioPharma]] and [[Biogen Idec]] for treatment of a variety of advanced [[solid tumor]]s. It binds to and inhibits the functional activity of [[Alpha-5 beta-1|α5β1]] [[integrin]].<ref>{{cite journal | vauthors = Ng CM, Bai S, Takimoto CH, Tang MT, Tolcher AW | title = Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients | journal = Cancer Chemotherapy and Pharmacology | volume = 65 | issue = 2 | pages = 207–17 | date = January 2010 | pmid = 19468731 | doi = 10.1007/s00280-009-1023-8 | s2cid = 23035675 }}</ref> |
|||
It is thought to reduce metastases. Early results show potential in [[renal cell cancer]]s.{{citation needed|date=April 2016}} |
|||
== References == |
|||
{{reflist}} |
|||
== External links == |
|||
* [http://www.pdl.com/index.cfm?navId=54 Official website] |
|||
{{Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems}} |
|||
[[Category:Monoclonal antibodies for tumors]] |
|||
{{monoclonal-antibody-stub}} |
|||
{{antineoplastic-drug-stub}} |
|||